Theravance Biopharma (TBPH) Cash from Operations Growth (5y) (2018 - 2026)
Theravance Biopharma (TBPH) Cash from Operations Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Theravance Biopharma | 864.56 Mn | 469.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.98% |
| Dec 31, 2025 | 37.76% |
| Sep 30, 2025 | 39.00% |
| Jun 30, 2025 | 42.62% |
| Mar 31, 2025 | 22.70% |
| Dec 31, 2024 | 57.41% |
| Sep 30, 2024 | 34.95% |
| Jun 30, 2024 | 37.96% |
| Mar 31, 2024 | 58.31% |
| Dec 31, 2023 | 56.07% |
| Sep 30, 2023 | 44.91% |
| Jun 30, 2023 | 27.37% |
| Mar 31, 2023 | -17.35% |
| Dec 31, 2022 | 26.52% |
| Sep 30, 2022 | 23.30% |
| Jun 30, 2022 | 19.85% |
| Mar 31, 2022 | 12.22% |
| Dec 31, 2021 | -8.58% |
| Sep 30, 2021 | -29.60% |
| Jun 30, 2021 | -9.29% |